References
- Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009; 17:55 - 67; http://dx.doi.org/10.1007/s10787-009-8049-8; PMID: 19340409
- Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10:181 - 93; http://dx.doi.org/10.1038/nrc2809; PMID: 20168319
- Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, Landesberg G, Crichton I, Wu W, Puré E, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med 2012; 4:32ra54; http://dx.doi.org/10.1126/scitranslmed.3003787; PMID: 22553252
- Markosyan N, Chen EP, Ndong VN, Yao Y, Sterner CJ, Chodosh LA, Lawson JA, Fitzgerald GA, Smyth EM. Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. Carcinogenesis 2011; 32:1441 - 9; http://dx.doi.org/10.1093/carcin/bgr134; PMID: 21771729
- Markosyan N, Chen EP, Evans RA, Ndong V, Vonderheide RH, Smyth EM. Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. Breast Cancer Res 2013; 15:R75; http://dx.doi.org/10.1186/bcr3469; PMID: 24004819
- Chen EP, Markosyan N, Connolly E, Lawson JA, Li X, Grant GR, Grosser T, Fitzgerald GA, Smyth EM. Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function. Carcinogenesis 2014; Forthcoming http://dx.doi.org/10.1093/carcin/bgu053; PMID: 24590894
- Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012; 33:119 - 26; http://dx.doi.org/10.1016/j.it.2011.12.001; PMID: 22277903
- Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207 - 12; http://dx.doi.org/10.1016/j.coi.2011.12.009; PMID: 22236695
- Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123:2625 - 35; http://dx.doi.org/10.1182/blood-2013-11-492231; PMID: 24578504
- Duivenvoorden R, Tang J, Cormode DP, Mieszawska AJ, Izquierdo-Garcia D, Ozcan C, Otten MJ, Zaidi N, Lobatto ME, van Rijs SM, et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun 2014; 5:3065; PMID: 24445279